Clinical trials: Epilepsy
Epilepsy
Epilepsy Seizure Detection With Innovative Tripolar EEG (tEEG)
Concurrent electroencephalography (EEG) and new tripolar EEG (tEEG) will be recorded from adult and pediatric patients. In some patients stereo EEG (sEEG) will also be recorded concurrently.
- Trial name
- NCT05944692
- Testing
- Tripolar electroencephalography
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- CREmedical
Epilepsy
Biomarker Targeted Stimulation for Epileptiform Events
This is a multicenter, prospective, controlled study designed to evaluate treatment with the BTS System.
- Trial name
- BTSEE (NCT06424977)
- Testing
- Biomarker Targeted Stimulation (BTS)
- Volunteers
- 40 people
- Sponsor
- Cadence Neuroscience
Dravet Syndrome
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS.
- Trial name
- NCT06660394
- Testing
- LP352
- Where
- 105 sites in United States, Australia and 16 more
- Volunteers
- 108 people
- Sponsor
- Longboard Pharmaceuticals
Focal Onset Seizures
SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
This is a Phase 2b open-label extension study to evaluate the long-term safety and efficacy of SPN-817.
- Trial name
- NCT07141329
- Testing
- SPN-817
- Where
- 8 sites in United States, Australia
- Volunteers
- 100 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Epilepsy, Epilepsy (Treatment Refractory)
Diagnosing Epilepsy To EffeCT Change
The purpose of this research is to address the challenges of diagnosing and long-term management of epilepsy in participants whose seizures are not well captured by standard electroencephalography (EEG) tests and who cannot use…
- Trial name
- DETECT (NCT07110337)
- Testing
- Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system)
- Where
- 23 sites in United States
- Volunteers
- 210 people
- Sponsor
- Epiminder America, Inc.
Focal Seizure, Epilepsy
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure…
- Conditions
- Focal Seizure, Epilepsy, Focal Epilepsy
- Trial name
- FOCUS 1 (NCT07563881)
- Testing
- RAP-219
- Where
- 18 sites in United States, South Korea
- Volunteers
- 333 people
- Sponsor
- Rapport Therapeutics Inc.
Dravet Syndrome
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
ENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged ≥6 to <36 months (Part 1A), aged ≥48 months to <18 years (Part 1B), and…
- Trial name
- ENDEAVOR (NCT05419492)
- Testing
- ETX101
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 113 people
- Sponsor
- Encoded Therapeutics
Epilepsy, Epilepsy (Treatment Refractory)
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
The purpose of this research is to address the challenges of correctly monitoring, managing, and diagnosing epilepsy in participants whose seizures are not well captured by standard electroencephalography (EEG) tests and who…
- Trial name
- DETECT LTFU (NCT07110454)
- Testing
- Previous receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system)
- Where
- 21 sites in United States
- Volunteers
- 210 people
- Sponsor
- Epiminder America, Inc.
Drug Resistant Epilepsy
A First in hUman Study for Resistant Epilepsy With the Vagus Nerve stimulatiOn Device by syneRgia medicAl
This is an open label, single arm, interventional, prospective first in human study, designed to evaluate the safety of the NAO.VNS SYSTEM.
- Trial name
- AURORA (NCT06340802)
- Testing
- VNS Treatment
- Where
- 2 sites in Belgium
- Volunteers
- 5 people
- Sponsor
- Synergia Medical
Epilepsy
Pharmacokinetics Study of VALTOCO® in Pediatric Subjects With Epilepsy
This is a Phase 1/2a, open-label, single-dose, PK study of VALTOCO with open-label safety period in pediatric epilepsy subjects age 2 to 5 years.
- Trial name
- NCT05076838
- Testing
- Diazepam Nasal Spray [Valtoco]
- Where
- 13 sites in United States
- Volunteers
- 36 people
- Sponsor
- Neurelis, Inc.
Dravet Syndrome
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.
- Trial name
- NCT06872125
- Testing
- zorevunersen
- Where
- 61 sites in United States, China and 6 more
- Volunteers
- 170 people
- Sponsor
- Stoke Therapeutics, Inc
Epilepsies, Myoclonic, Drug Resistant Epilepsy
Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies
The primary purpose of this study is to provide continued access of lorcaserin to participants with Dravet syndrome and other refractory epilepsies.
- Trial name
- NCT04457687
- Testing
- Lorcaserin
- Where
- 22 sites in United States, Canada
- Sponsor
- Eisai Inc.
Partial Epilepsy
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
- Trial name
- NCT05067634
- Testing
- Xcopri
- Where
- 35 sites in United States, Australia and 5 more
- Volunteers
- 154 people
- Sponsor
- SK Life Science, Inc.
Drug Resistant Epilepsy, Refractory Epilepsy
Post-Market Real-World Evidence Registry for the NeuroOne OneRF® Ablation System for Epilepsy
This is a multi-site registry study that aims to collect real-world clinical outcomes and device performance of the OneRF Ablation System.
- Trial name
- NCT07546253
- Testing
- Participants are not assigned an intervention as part of the study.
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- NeuroOne Medical Technologies Corporation
Focal Seizure, Epilepsy
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure…
- Conditions
- Focal Seizure, Epilepsy, Focal Epilepsy
- Trial name
- FOCUS 2 (NCT07594119)
- Testing
- RAP-219
- Where
- 13 sites in United States
- Volunteers
- 312 people
- Sponsor
- Rapport Therapeutics Inc.
KCNT1-Related Epilepsy
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy
This trial will evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsy
- Trial name
- KYRON (NCT07600736)
- Testing
- ABS-1230
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Actio Biosciences, Inc.
Developmental and Epileptic Encephalopathy
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
This (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed…
- Trial name
- NCT06908226
- Testing
- LP352
- Where
- 88 sites in United States, Australia and 15 more
- Volunteers
- 324 people
- Sponsor
- Longboard Pharmaceuticals
Partial Epilepsy
A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year Olds
Primary objective: To evaluate the safety and tolerability of cenobamate in Japanese pediatric subjects 2-17 years of age with partial-onset (focal) seizures
- Trial name
- NCT07594158
- Testing
- Cenobamate (tablet) for 12 to < 18 year olds, Cenobamate (syrup) for 2 to < 18 year olds
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Primary Generalized Tonic-Clonic Seizures
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic…
- Trial name
- X-ACKT (NCT05667142)
- Testing
- XEN1101
- Where
- 138 sites in United States, Argentina and 18 more
- Volunteers
- 160 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Focal Onset Seizures
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
- Trial name
- NCT05716100
- Testing
- XEN1101
- Where
- 98 sites in United States, Argentina and 19 more
- Volunteers
- 360 people
- Sponsor
- Xenon Pharmaceuticals Inc.